This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US
September 27-30, 2022
Boston Convention and Exhibition CenterBoston, MA

Mark Plavsic
Chief Technical Officer, Fate Therapeutics at Fate Therapeutics Inc


Mark is a Chief Technical Officer at Fate Therapeutics, a clinical stage cell therapy company located in San Diego, CA. Prior to joining Fate Therapeutics, Dr. Plavsic served as Chief Technical Officer at Lysogene, a late stage clinical development gene therapy company with headquarters in Paris, France. Prior to joining Torque, Mark served as Head of Product Biosafety at Genzyme/Sanofi responsible for process improvements and bio-safety of biological products and associated manufacturing processes. Previously, Mark was in charge of gene therapy development at Genzyme, overseeing the upstream, downstream, formulation and analytical developments of viral vectors used in gene therapy applications. Prior to Genzyme, Mark held senior positions with AstraZeneca, Q-One Biotech, and Life Technologies, Inc. Mark’s technical experience spans across a wide spectrum of drug development and manufacturing activities, including raw materials, R&D, QC testing, GLP non-clinical studies, process development, GMP manufacturing, GMP contract testing, and GMP contract manufacturing.

Mark’s education includes doctor of veterinary medicine (DVM) degree, MSc, and PhD degree in virology.

Agenda Sessions

  • Overcoming the Scale Up and Manufacturing Challenges of Next Generation “Off the Shelf” Allogeneic Cell Therapies